Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.8
3.9
Journals
Biomedicines
Special Issues
Skin Diseases and Cell Therapy
share announcement

Skin Diseases and Cell Therapy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1162

Special Issue Editors

Dr. Nives Pondeljak

E-Mail
Guest Editor
Department of Dermatovenereology, General Hospital "Dr. Ivo Pedišić", Sisak, Croatia
Interests: clinical dermatology; dermatology
Dr. Maryam Heidari Kharaji

E-Mail Website
Guest Editor
Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO, USA
Interests: dermatology; cancer; cell therapy
Prof. Dr. Mirna Šitum

E-Mail Website
Guest Editor
Department of Dermatology and Venerology, University Hospital Center “Sestre Milosrdnice”, University of Zagreb, 10000 Zagreb, Croatia
Interests: skin cancer; transdermal and topical delivery; skin

Special Issue Information

Dear Colleagues,

The field of dermatology is rapidly evolving, driven by advances in molecular biology that enhance our understanding of skin diseases and their underlying mechanisms. This Special Issue aims to provide a platform for researchers focused on experimental and laboratory medicine that addresses the molecular pathways contributing to various skin conditions, including but not limited to psoriasis, atopic dermatitis, vitiligo, alopecia, cutaneous leishmaniasis and skin fibrosis, squamous cell carcinoma, basal cell carcinoma, and melanoma. We invite contributions that explore novel biological and molecular mechanisms, as well as innovative therapeutic strategies emerging from experimental studies.

Our goal is to bridge laboratory discoveries with potential novel treatments that can effectively target the complexities of chronic inflammatory skin diseases and other dermatological disorders. We seek original research articles, methodologies, and reviews that delve into the biochemical interactions, immune responses, and genetic factors influencing skin health. Contributions that elucidate the mechanistic aspects of existing and emerging therapies will be particularly significant.

By fostering collaboration between molecular researchers and clinical dermatologists, we hope to catalyze the development of more effective, personalized treatment approaches for patients suffering from chronic skin diseases.

We look forward to your submissions that enhance our comprehension and treatment of dermatological diseases through rigorous scientific inquiry.

Dr. Nives Pondeljak
Dr. Maryam Heidari Kharaji
Prof. Dr. Mirna Šitum
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dermatology
  • psoriasis, atopic dermatitis, vitiligo, alopecia, cutaneous leishmaniasis, and skin fibrosis
  • skin cancers
  • innovative therapeutic strategies
  • molecular mechanisms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

25 pages, 877 KB  
Review
Therapeutic Opportunities in Melanoma Through PRAME Expression
by Mislav Mokos, Ivana Prkačin, Klara Gaćina, Ana Brkić, Nives Pondeljak and Mirna Šitum
Biomedicines 2025, 13(8), 1988; https://doi.org/10.3390/biomedicines13081988 - 15 Aug 2025
Viewed by 407
Abstract
Background: Melanoma is one of the most aggressive types of skin cancer. Its diagnosis appears to be challenging due to morphological similarities to benign melanocytic lesions. Even though histopathological evaluation is the diagnostic gold standard, immunohistochemistry (IHC) proves to be useful in challenging [...] Read more.
Background: Melanoma is one of the most aggressive types of skin cancer. Its diagnosis appears to be challenging due to morphological similarities to benign melanocytic lesions. Even though histopathological evaluation is the diagnostic gold standard, immunohistochemistry (IHC) proves to be useful in challenging cases. Preferentially Expressed Antigen in Melanoma (PRAME) has emerged as a promising diagnostic, prognostic, and therapeutic marker in melanoma. Methods: This review critically examines the role of PRAME across clinical domains. It presents an evaluation of PRAME’s diagnostic utility in differentiating melanomas from benign nevi, its prognostic significance across melanoma subtypes, and therapeutic applications in emerging immunotherapy strategies. An extensive analysis of the current literature was conducted, with a focus on PRAME expression patterns in melanocytic lesions and various malignancies, along with its integration into IHC protocols and investigational therapies. Results: PRAME demonstrates high specificity and sensitivity in distinguishing melanoma from benign melanocytic proliferations, particularly in challenging subtypes such as acral, mucosal, and spitzoid lesions. Its overexpression correlates with poor prognosis in numerous malignancies. Therapeutically, PRAME’s HLA class I presentation enables T-cell-based targeting. Early-phase trials show promising results using PRAME-directed TCR therapies and bispecific ImmTAC agents. However, immune evasion mechanisms (i.e., heterogeneous antigen expression, immune suppression in the tumor microenvironment, and HLA downregulation) pose significant challenges to therapy. Conclusions: PRAME is a valuable biomarker for melanoma diagnosis and a promising target for immunotherapy. Its selective expression in malignancies supports its clinical utility in diagnostic precision, prognostic assessment, and precision oncology. Ongoing research aimed at overcoming immunological barriers will be essential for optimizing PRAME-directed therapies and establishing their place in the personalized management of melanoma. Full article
(This article belongs to the Special Issue Skin Diseases and Cell Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Review

14 pages, 1282 KB  
Systematic Review
Actinic Cheilitis: A Systematic Review and Meta-Analysis of Interventions, Treatment Outcomes, and Adverse Events
by Matthäus Al-Fartwsi, Anne Petzold, Theresa Steeb, Lina Amin Djawher, Anja Wessely, Anett Leppert, Carola Berking and Markus V. Heppt
Biomedicines 2025, 13(8), 1896; https://doi.org/10.3390/biomedicines13081896 - 4 Aug 2025
Viewed by 585
Abstract
Introduction: Actinic cheilitis (AC) is a common precancerous condition affecting the lips, primarily caused by prolonged ultraviolet radiation exposure. Various treatment options are available. However, the optimal treatment approach remains a subject of debate. Objective: To summarize and compare practice-relevant interventions for AC. [...] Read more.
Introduction: Actinic cheilitis (AC) is a common precancerous condition affecting the lips, primarily caused by prolonged ultraviolet radiation exposure. Various treatment options are available. However, the optimal treatment approach remains a subject of debate. Objective: To summarize and compare practice-relevant interventions for AC. Materials and Methods: A pre-defined protocol was registered in PROSPERO (CRD42021225182). Systematic searches in Medline, Embase, and Central, along with manual trial register searches, identified studies reporting participant clearance rates (PCR) or recurrence rates (PRR). Quality assessment for randomized controlled trials (RCTs) was conducted using the Cochrane Risk of Bias tool 2. Uncontrolled studies were evaluated using the tool developed by the National Heart, Lung, and Blood Institute. The generalized linear mixed model was used to pool proportions for uncontrolled studies. A pairwise meta-analysis for RCTs was applied, using the odds ratio (OR) as the effect estimate and the GRADE approach to evaluate the quality of the evidence. Adverse events were analyzed qualitatively. Results: A comprehensive inclusion of 36 studies facilitated an evaluation of 614 participants for PCR, and 430 patients for PRR. Diclofenac showed the lowest PCR (0.53, 95% confidence interval (CI) [0.41; 0.66]), while CO2 laser showed the highest PCR (0.97, 95% CI [0.90; 0.99]). For PRR, Er:YAG laser showed the highest rates (0.14, 95% CI [0.08; 0.21]), and imiquimod the lowest (0.00, 95% CI [0.00; 0.06]). In a pairwise meta-analysis, the OR indicated a lower recurrence rate for Er:YAG ablative fractional laser (AFL)-primed methyl-aminolevulinate photodynamic therapy (MAL-PDT) (Er:YAG AFL-PDT) compared to methyl-aminolevulinate photodynamic therapy (MAL-PDT) alone (OR = 0.22, 95% CI [0.06; 0.82]). The CO2 laser showed fewer local side effects than the Er:YAG laser, while PDTs caused more skin reactions. Due to qualitative data, comparability was limited, highlighting the need for individualized treatment. Conclusions: This study provides a complete and up-to-date evidence synthesis of practice-relevant interventions for AC, identifying the CO2 laser as the most effective treatment and regarding PCR and imiquimod as most effective concerning PRR. Full article
(This article belongs to the Special Issue Skin Diseases and Cell Therapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop